Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases

키워드

참고문헌 (26)

1. Iyo M, "Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis", J Clin Psychopharmacol, 33, pp.398~404 (2013)
2. Chouinard G, "Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment", Schizophr Res, 5, pp.21~33 (1991)
3. Chouinard G, "Antipsychotic-induced dopamine supersensitivity psychosis : pharmacology, criteria, and therapy", Psychother Psychosom, 86, pp.189~219 (2017)
4. Kimura H, "Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity", Behav Brain Res, 403, pp.113126~ (2021)
5. Takase M, "Dopamine supersensitivity psychosis and dopamine partial agonist : a retrospective survey of failure of switching to aripiprazole in schizophrenia", J Psychopharmacol, 29, pp.383~389 (2015)
6. Rajkumar RP, "Supersensitivity psychosis and its response to asenapine in a patient with delusional disorder", Case Rep Psychiatry, 2014, pp.215732~ (2014)
7. Takao N, "Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine", BMJ Case Rep, 14, pp.e242495~ (2021)
8. Chouinard G, "Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis", Prog Neuropsychopharmacol Biol Psychiatry, 18, pp.1129~1141 (1994)
9. Nakata Y, "Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia", Int Clin Psychopharmacol, 32, pp.169~173 (2017)
10. Kimura H, "Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis", Schizophr Res, 145, pp.130~131 (2013)
11. Kimura H, "A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis", Schizophr Res, 155, pp.52~58 (2014)
12. Kimura H, "Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis : results of a 2-year prospective study, including an additional 1-year follow-up", J Psychopharmacol, 30, pp.795~802 (2016)
13. Tachibana M, "Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity : a retrospective analysis", Asian J Psychiatr, 24, pp.28~32 (2016)
14. Niitsu T, "A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis : the ROADS study", Asian J Psychiatr, 53, pp.102369~ (2020)
15. Kobayashi R, "Successful rechallenge with paliperidone after clozapine treatment for a patient with dopamine supersensitivity psychosis", SAGE Open Med Case Rep, 8, pp.2050313~ (2020)
16. Shigenori Tadokoro, "Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report", Clinical Psychopharmacology and Neuroscience, 15(1), pp.79~81 (2017), 대한정신약물학회[DOI]
17. Kanahara N, "Combination therapy of electroconvulsive therapy and aripiprazole for dopamine supersensitivity psychosis", Schizophr Res, 202, pp.398~400 (2018)
18. Kanahara N, "The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis : a case series from an open study", Int Clin Psychopharmacol, 35, pp.338~344 (2020)
19. Meiji Seika Pharma Co., Ltd, "The manual of Sycrest sublingual tablets 5mg, 10mg Interview Form" (2020), Meiji Seika Pharma Co., Ltd
20. Charron A, "5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity", Eur Neuropsychopharmacol, 25, pp.2381~2393 (2015)
21. Hashimoto T, "Lack of dopamine supersensitivity in rats after chronic administration of blonanserin : comparison with haloperidol", Eur J Pharmacol, 830, pp.26~32 (2018)
22. Gray JA, "The pipeline and future of drug development in schizophrenia", Mol Psychiatry, 12, pp.904~922 (2007)
23. Baba S, "Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range", J Pharmacol Sci, 127, pp.326~331 (2015)
24. Shahid M, "Asenapine : a novel psychopharmacologic agent with a unique human receptor signature", J Psychopharmacol, 23, pp.65~73 (2009)
25. Shinichiro Ochi, "Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report", Clinical Psychopharmacology and Neuroscience, 17(4), pp.559~563 (2019), 대한정신약물학회[DOI]
26. Takekita Y, "Divergence of dose-response with asenapine : a cluster analysis of randomized, double-blind, and placebo control study", CNS Spectr, 27, pp.369~377 (2022)

관련 논문AI추천